Nagah Elmusharaf

Treatment patterns and outcomes of unfit and elderly patients with Mantle cell lymphoma unfit for standard immunochemotherapy: A UK and Ireland analysis

R. Clifford, A. Hayat, P. McKay, 2021, British journal of haematology.

Ibrutinib and rituximab versus fludarabine, cyclophosphamide, and rituximab for patients with previously untreated chronic lymphocytic leukaemia (FLAIR): interim analysis of a multicentre, open-label, randomised, phase 3 trial.

A. Schuh, D. Cairns, J. Shingles, 2023, The Lancet. Oncology.

Chronic Lymphocytic Leukemia Therapy Guided by Measurable Residual Disease.

L. Duley, S. Paneesha, O. Sheehy, 2023, The New England journal of medicine.

Phase I/II results of ceralasertib as monotherapy or in combination with acalabrutinib in high-risk relapsed/refractory chronic lymphocytic leukemia

Jeffrey R. Whiteaker, A. Paulovich, C. Wun, 2023, Therapeutic advances in hematology.

Venetoclax ramp‐up strategies for chronic lymphocytic leukaemia in the United Kingdom: a real world multicentre retrospective study

A. Schuh, N. Martínez-Calle, T. Eyre, 2023, British journal of haematology.